Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

NuvOx Pharma (United States) | Researchclopedia

Back to institutions

NuvOx Pharma (United States)

Tucson, Arizonacompany

67

Works

4,535

Citations

35

h-index

Top Research Topics

Cancer, Hypoxia, and Metabolism Nanoplatforms for cancer theranostics Ultrasound and Hyperthermia Applications

Top Researchers

David B. Wilson Niger Delta University

550 works28,571 citationsh-index: 90

Recent Research

Abstract PS3-13-10: Immunomodulation of Tumor Microenvironment by Reversing Hypoxia

P. Egwon,Aparna Nanduru,et al.

20260 citations

Traumatic Brain Injury and Neurovascular Disturbances

Glioma Diagnosis and Treatment

Antioxidant Activity and Oxidative Stress

Fungal Biology and Applications

Hemoglobin structure and function

Skin Protection and Aging

Cancer Research and Treatments

Pancreatic and Hepatic Oncology Research

Medical Imaging Techniques and Applications

Joe Y. Chang The University of Texas MD Anderson Cancer Center

652 works27,761 citationsh-index: 85

Anton Simeonov National Institutes of Health

700 works25,335 citationsh-index: 85

George L. Kenyon Rutgers, The State University of New Jersey

274 works11,766 citationsh-index: 58

Evan C. Unger NuvOx Pharma (United States)

220 works8,468 citationsh-index: 48

Charles E. McKenna University of Southern California

450 works6,784 citationsh-index: 43

Abstract PS4-06-07: Yes/src kinase inhibitor nxp900, currently in clinical development, combines synergistically with fulvestrant against luminal a breast cancer cell lines in vitro and in vivo

Iñigo Lanzagorta-Calvillo,Boback Kaghazchi,et al.

20260 citations

Validating the Effects of Multivitamins on Nutrient Status Using Non-Invasive Spectroscopy

Shelly N. Hester,Melanie Riggs,et al.

20260 citations

5 Immunomodulation of tumor microenvironment in triple negative breast cancer by reversing hypoxia with NanO2, a novel oxygen delivery agent

Aparna Nanduru,Peter Egwom,et al.

20250 citations

CTNI-78. A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO₂TM combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE

Michael Badruddoja,Crystal Placencia,et al.

20250 citations

Assessment of Patient Safety Culture Among Citizens: A Survey Study

Micaela La Regina,Chiara Parretti,et al.

20251 citations